Survey results suggest that patients would benefit from a quick-acting, easy-to-use drug such as APL130277 to treat "off" episodes that provides relief from the quality-of-life burden without imposing a high treatment burden; currently, when presented with the opportunity to use Apokyn
, most patients choose not to initiate treatment, primarily due to the injection and possible skin irritation and inflammation.
3 November 2011 - French Ipsen (EPA:IPN) has sold its North American development and marketing rights for Parkinson's disease medicine Apokyn
to UK Britannia Pharmaceuticals Ltd.
, which has orphan drug status, will be commercially available in July, with distribution to be handled through a specialty pharmacy network, according to a spokesperson for Mylan Laboratories Inc.
An alternative to Apokyn
in approaching the problem of off episodes is rasagiline, a potent once-daily second-generation MAO type-B inhibitor that reduces the frequency of such episodes by blocking dopamine breakdown, although it's not useful as rescue therapy during an episode.
This injectable dopamine agonist, known as Apokyn
, recently received Food and Drug Administration approval as the first and only acute or rescue therapy for off episodes in Parkinson's disease patients.
PharmaCare Specialty Pharmacy has been selected as a preferred provider of Apokyn
, Bertek Pharmaceuticals Inc.